<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149713">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963988</url>
  </required_header>
  <id_info>
    <org_study_id>2013-05-127</org_study_id>
    <secondary_id>ksleedr</secondary_id>
    <nct_id>NCT01963988</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy Between Transurethral Coagulation and Transurthral Resection of Ulcer in Bladder Pain Syndrome Patients</brief_title>
  <official_title>Pilot Study for Comparison of the Efficacy Between Transurethral Coagulation and Transurthral Resection of Ulcer in Bladder Pain Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the EAU (European Association of Urology) guidelines, the ulcer type bladder pain
      syndrome (BPS) should be treated with transurethral resection (TUR) or coagulation (TUC) of
      ulcer.

      But, Up to date, there was no study to compare the therapeutic efficacy of TUR with TUC in
      ulcer type BPS patients.

      We assume TUR have a more therapeutic effect than TUC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>change of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom index score</measure>
    <time_frame>12 months later after each treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of voiding dairy parameters(mean number of micturition,Urgency etc) after each treatment</measure>
    <time_frame>1,3,6,9 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF)</measure>
    <time_frame>1,3,6,9 and 12months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Global Response Assessment(GRA) score</measure>
    <time_frame>1,3,6,9 and 12 momths</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of EQ-5D (EuroQOL five dimensions) Health Questionnaire score</measure>
    <time_frame>1,3,6,9 and 12months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Patient Global Assessment(PGA)</measure>
    <time_frame>12months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Brief Pain Inventory-short form(BPI-sf) score</measure>
    <time_frame>9 and 12months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence of Bladder Pain Syndrome on the cystoscopy</measure>
    <time_frame>mandatory: 3 and 12mo/ optional: 1,6 and 9months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The optional cystoscopic examination will be carried out if a patient complains recurrent bladder or pelvic pain/discomfort(ex:Pressure...)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bladder Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Transurethral Coagulation (TUC)</arm_group_label>
    <description>This cohort patients will be managed with Transurethral Coagulation (TUC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral Resection(TUR)</arm_group_label>
    <description>This cohort patients will be managed with Transurethral Resection(TUR).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be enrolled diagnosed with bladder pain syndrome by ESSIC proposal.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged 18 yrs or greater

          2. Patients diagnosed with BPS(Bladder Pain Syndrome)

          3. Symptom persisted more than 6 months

          4. Pain VAS â‰¥4

          5. O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) scores 12 or greater with
             pain and nocturia domain scores &gt; 2.

          6. Pelvic Pain and Urgency/Frequency Patient Symptom Scale(PUF) &gt;13

          7. No history of cystoscopy within 2yrs.

        Exclusion Criteria:

          1. history of augmentation cystoplasty due to BPS

          2. child-bearing potential, pregnant or nursing women.

          3. mean voided volume lesser than 40ml or over than 400ml.

          4. hematuria exceeds 1+ in the urinary dipstick (dipstick) examination.

          5. urinary tract infection during run-in periods.

          6. genitourinary tuberculosis or bladder,urethral and prostate cancer

          7. recurrent urinary tract infection

          8. history of hysterectomy ,mid-urethral sling,pelvic organ prolapse repair,vaginal
             delivery or Cesarean section,prostate operation or treatment etc within 6months.

          9. neurologic disease history of cerebral infarction,multiple sclerosis or parkinsonism
             etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
    <phone>82-2-3410-3554</phone>
    <email>keleedr@skku.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun Wook You, M.D.</last_name>
    <phone>82-2-3410-1268</phone>
    <email>khdoct29@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
      <phone>82-2-3410-3554</phone>
      <email>ksleedr@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Wook You, M.D.</last_name>
      <phone>82-2-3410-1268</phone>
      <email>khdoct29@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 24, 2014</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>professor,MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Bladder Pain Syndrome</keyword>
  <keyword>transurethral Resection of Ulcer</keyword>
  <keyword>transurethral Coagulation of Ulcer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
